➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Merck
Baxter
Johnson and Johnson
Colorcon

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRINCIDOFOVIR

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Brincidofovir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02087306 ↗ Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection Completed Chimerix Phase 3 2014-03-01 This is a multicenter study of Brincidofovir (CMX001) (BCV) administered twice weekly (BIW) for the treatment of AdV infection detected during asymptomatic AdV viremia or during symptomatic AdV infection. After completing a screening assessment to confirm study eligibility, all enrolled subjects will undergo a treatment period of 12 weeks. Beginning on Day 1, adult (≥ 18 years) and adolescent (13-17 years) subjects weighing > 50 kg will receive BCV 100 mg BIW; children up to 12 years of age will receive weight-based doses of 2 mg/kg BIW, not-to-exceed a total dose of 200 mg/week.
NCT02167685 ↗ The Chimerix CMX001 Registry Recruiting Chimerix N/A 2014-01-01 The prospective observational study is to establish a registry database to evaluate the potential impact of prior treatment with CMX001 on the long-term incidence of specific events, such as outcomes, late CMV and other Double-stranded DNA virus associated events, s well as survival rates in subjects previously enrolled in selected clinical studies of CMX001. Each Registry participant will be followed for a period of approximately 3 years from their enrollment in the Registry.
NCT02271347 ↗ An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease Withdrawn Chimerix Phase 2 2014-10-01 The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brincidofovir

Condition Name

Condition Name for Brincidofovir
Intervention Trials
Adenovirus 4
Outcomes 1
EVD 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brincidofovir
Intervention Trials
Adenoviridae Infections 5
Infection 1
Communicable Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brincidofovir

Trials by Country

Trials by Country for Brincidofovir
Location Trials
United States 87
Canada 2
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brincidofovir
Location Trials
California 6
Colorado 5
Illinois 4
Pennsylvania 4
Tennessee 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brincidofovir

Clinical Trial Phase

Clinical Trial Phase for Brincidofovir
Clinical Trial Phase Trials
Phase 3 3
Phase 2 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brincidofovir
Clinical Trial Phase Trials
Not yet recruiting 3
Completed 2
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brincidofovir

Sponsor Name

Sponsor Name for Brincidofovir
Sponsor Trials
Chimerix 10
SymBio Pharmaceuticals 1
Food and Drug Administration (FDA) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brincidofovir
Sponsor Trials
Industry 11
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
McKesson
Express Scripts
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.